We are international
Donate
TEXT SIZE   


03.26.15
March 26, 2015
Share the Minute Facebook Tweet!
Clinical Trials
Donate to the IMF
 


Thi
s week's question: Does the type of myeloma impact the choice of treatment?

 

Multiple Myeloma Bone Study
 

Ixazomib in Newly Diagnosed and/or Relapsed/Refractory Myeloma

 

Join the conversation about myeloma on the Smart Patients Message Board

 

 Upcoming Events

 


Friday, April 10, 2015
2015 Kubik Multiple Myeloma Benefit
Rowlett, Texas

 


Saturday, April 11, 2015
Myeloma Center Workshop
Dallas, Texas

 

 
Watch the IMF Mambo for Myeloma & Support This Challenge

 

Watch the Staten Island Dance & Arts Center Mambo for Myeloma!

 

x

Pieter Sonneveld to Receive 2015 Robert A. Kyle Award


IMF will present Prof. Dr. Pieter Sonneveld with the 13th Annual Robert A. Kyle Lifetime Achievement Award at a ceremony during the International Myeloma Working Group (IMWG) Summit in Vienna, Austria on June 9, 2015. IMF Chairman Dr. Brian Durie said of Dr. Sonneveld and his pending honor, “His work perfectly reflects the words of Dr. William Mayo, founder of Mayo Clinic, who challenged the nature of patient care nearly a century ago when he said ‘The needs of the patient are the only needs to be considered.’ ” Read more about Prof. Dr. Pieter Sonneveld HERE.

x

Improving the Immune System in Myeloma Patients

Dr. Brian Durie writes this week about emerging monoclonal antibody therapies that show promise in boosting the immune system in myeloma patients. As myeloma evolves, it reduces normal plasma cells and often reduces the ability for a patient to fight infections. In order for the immune system to bounce back, the myeloma cells must be killed. CLICK HERE to read Dr. Durie’s blog.

x

Ixazomib Clinical Trial Seeking Myeloma Patients


 

Takeda Oncology is recruiting myeloma patients to participate in a multicenter, open-label study of ixazomib, its investigational oral proteasome inhibitor. Eligible patients have not received prior systemic treatment for myeloma and are ineligible for high-dose therapy stem cell transplantation due to age or comorbid diseases, or have relapsed/refractory myeloma. Ixazomib was granted orphan drug designation in myeloma in both the U.S. and Europe in 2011, and is the first oral proteasome inhibitor to enter Phase 3 clinical trials. CLICK HERE for more information on the clinical trial.

x

Replay of Immune System Teleconference Now Available

If you missed last week’s Living Well with Myeloma teleconference on the topic of “Understanding the Immune System in Myeloma,” it is now available via the IMF’s replay. The teleconference, which dealt with the various parts of the immune system and how they vary between a healthy person and a myeloma patient, was hosted by the IMF’s Dr. Brian Durie, who also explained different immune therapies as well as the strides made by the IMF’s Black Swan Research Initiative®. CLICK HERE to catch up on the news and listen to the replay.

x

Rep. Brian Higgins Sponsors National #MAM Resolution

 

 

Myeloma Awareness Month is wrapping up this year with the introduction of a national resolution (H. Res. 174) to designate March as "National Myeloma Awareness Month.” The resolution would add to the immense successes of patient advocates across the country who have already received proclamations for their individual states, counties, and cities. The resolution sponsor, Rep. Brian Higgins (D-NY), has been a strong ally of the IMF for the past several years, and has also been the lead sponsor of the Cancer Drug Coverage Parity Act since its inception in 2009. The IMF thanks Rep. Higgins for his leadership, along with the two other original sponsors, Rep. Eleanor Norton (D-NY) and Rep. Alcee Hastings (D-FL). To find out more about the resolution and to see if your representative is a sponsor, please CLICK HERE.

Join Our Mailing List

 
12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
IMF Hotline: 800-452-2873 or 818-487-7455
Privacy Policy | Unsubscribe
www.myeloma.org

 related videos
 related articles
ASCO 2013: Dr. Jagannath - Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.
"Understanding Health Disparities in Cancer: The Case of Multiple Myeloma"
Understanding Freelite and Hevylite Tests
ASCO 2013: Dr. Jagannath - Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.
Best of ASH 2013: What Patients Need to Know
BLACK SWAN RESEARCH INITIATIVE™ DONOR LEVELS
BLACK SWAN RESEARCH INITIATIVE™ MEDIA CONTACT
BRAZIL WORKSHOP
California Support Group Leader’s Testimony Makes Huge Difference
Cancer Awareness Bracelets
Dr. Brian Durie, Chairman of the International Myeloma Foundation, Honored by Mayo Clinic With Distinguished Alumni Award
Global Myeloma Action Network (GMAN)
IMF Nurse Leadership Board (NLB) Survivorship Care Plan for Mutliple Myeloma published in the Clinical Journal of Oncology Nursing.
IMF's 8th Annual Comedy Celebration: Big Laughs, Big Success
International Myeloma Foundation (IMF) Funds First Large-Scale Screening to Identify and Treat Precursor of Blood Cancer Before Disease Develops
International Myeloma Foundation (IMF)
Flow Workshop Presentations
July 18-19, 2014
International Myeloma Foundation Mission Statement
Mensajero del Mieloma - Otoño 2012 - #903
Michael and Robin Tuohy of Connecticut Help to Pass State Oral Parity Bill
Myeloma Minute
March 26, 2015
Pierre S. Sayad Joins IMF as Senior Vice President, Global Medical Affairs and Strategic Partnerships
Pomalidomide News: Promising Results Increase Chances of Early Drug Approval
Raise Your Voice Web Series
Sign up TODAY for Advocacy Training Two-Part Online Series!
Supreme Court Upholds Affordable Care Act
The International Myeloma Foundation Applauds Wisconsin Gov. Scott Walker for Signing SB 300 (The Cancer Treatment Fairness Act) into Law
The Military Veterans Perspective on Living with Multiple Myeloma
What does ‘dysplasia’ mean within the bone marrow report?